Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

被引：618

作者：

Lawitz, Eric ^{[1
]}

Sulkowski, Mark S. ^{[2
]}

Ghalib, Reem ^{[3
]}

Rodriguez-Torres, Maribel ^{[4
]}

Younossi, Zobair M. ^{[5
]}

Corregidor, Ana ^{[6
]}

DeJesus, Edwin ^{[7
]}

Pearlman, Brian ^{[8
]}

Rabinovitz, Mordechai ^{[9
]}

Gitlin, Norman ^{[10
]}

Lim, Joseph K. ^{[11
,12
]}

Pockros, Paul J. ^{[13
]}

Scott, John D. ^{[14
]}

Fevery, Bart ^{[15
]}

Lambrecht, Tom ^{[16
]}

Ouwerkerk-Mahadevan, Sivi ^{[15
]}

Callewaert, Katleen ^{[15
]}

Symonds, William T. ^{[17
]}

Picchio, Gaston ^{[18
]}

Lindsay, Karen L. ^{[18
]}

Beumont, Maria ^{[15
]}

Jacobson, Ira M. ^{[19
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78215 USA

[2] Johns Hopkins Univ Sch Med, Baltimore, MD USA

[3] Texas Clin Res Inst, Arlington, TX USA

[4] Fdn Invest, San Juan, PR USA

[5] Inova Fairfax Hosp, Dept Med, Falls Church, VA USA

[6] Borland Groover Clin, Jacksonville, FL USA

[7] Orlando Immunol Ctr, Orlando, FL USA

[8] Atlanta Med Ctr, Atlanta, GA USA

[9] Univ Pittsburgh Med Ctr, Pittsburgh, PA USA

[10] Atlanta Gastroenterol Assoc, Atlanta, GA USA

[11] Yale Liver Ctr, New Haven, CT USA

[12] Yale Univ Sch Med, New Haven, CT USA

[13] Scripps Clin, La Jolla, CA 92037 USA

[14] Harborview Med Ctr, Seattle, WA USA

[15] Janssen Res & Dev, Beerse, Belgium

[16] Novellas Healthcare, Zellik, Belgium

[17] Gilead Sci Inc, Foster City, CA 94404 USA

[18] Janssen Res & Dev, Titusville, NJ USA

[19] Weill Cornell Med Coll, New York, NY USA

来源：

LANCET | 2014年 / 384卷 / 9956期

关键词：

HCV INFECTION; PHASE-3; TRIAL; DOUBLE-BLIND; ALPHA; 2A; PEGINTERFERON; BOCEPREVIR; TELAPREVIR; SVR;

D O I：

10.1016/S0140-6736(14)61036-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Interferon-free regimens are needed to treat hepatitis C virus (HCV) infections. We investigated the efficacy of combined simeprevir and sofosbuvir. Methods We enrolled patients with chronic HCV genotype 1 infections who had previously not responded to pegylated interferon (peginterferon) and ribavirin or were treatment naive. Patients were randomly assigned in a 2: 1: 2: 1 ratio to receive 150 mg simeprevir and 400 mg sofosbuvir daily for 24 weeks with (group 1) or without (group 2) ribavirin or for 12 weeks with (group 3) or without (group 4) ribavirin, in two cohorts: previous non-responders with METAVIR scores F0-F2 (cohort 1) and previous non-responders and treatment-naive patients with METAVIR scores F3-F4 (cohort 2). The primary endpoint was sustained virological response 12 weeks after stopping treatment (SVR12). Analysis was done by intention to treat. Safety data from cohorts 1 and 2 were pooled for analysis. This study is registered with ClinicalTrials. gov, number NCT01466790. Findings 168 patients were enrolled and randomised, and 167 started treatment (n=80 in cohort 1 and n=87 in cohort 2). SVR12 was achieved in 154 (92%) patients (n=72 [90%, 95% CI 81-96] in cohort 1 and n=82 [94%, 87-98] in cohort 2). The most common adverse events in the pooled groups were fatigue (n=52 [31%]), headache (n=33 [20%]), and nausea (n=26 [16%]). Grade 4 adverse events were seen in one (2%) of 54 patients in each of groups 1 and 3 and in three (10%) of 31 patients in group 2, whereas grade 3-4 events were reported in less than 5% of all patients, except increased blood amylase concentration. Serious adverse events were seen in four (2%) patients, all in groups 1 and 2. Four (2%) patients discontinued all study treatment because of adverse events, three before week 12. Interpretation Combined simeprevir and sofosbuvir was efficacious and well tolerated.

引用

页码：1756 / 1765

页数：10

共 21 条

[11]

Lawitz E, 2013, NEW ENGL J MED, V369, P678, DOI [10.1056/NEJMoa1214853, 10.1056/NEJMc1307641]

[12] VIROLOGY ANALYSES OF SIMEPREVIR IN PHASE 2B AND 3 STUDIES [J].

Lenz, O. ;

Verbinnen, T. ;

Fevery, B. ;

Tambuyzer, L. ;

Vijgen, L. ;

Peeters, M. ;

Buelens, A. ;

Beumont-Mauviel, M. ;

Picchio, G. ;

de Meyer, S. .

JOURNAL OF HEPATOLOGY, 2014, 60 (01) :S139-S140

[13] A New Equation to Estimate Glomerular Filtration Rate [J].

Levey, Andrew S. ;

Stevens, Lesley A. ;

Schmid, Christopher H. ;

Zhang, Yaping ;

Castro, Alejandro F., III ;

Feldman, Harold I. ;

Kusek, John W. ;

Eggers, Paul ;

Van Lente, Frederick ;

Greene, Tom ;

Coresh, Josef .

ANNALS OF INTERNAL MEDICINE, 2009, 150 (09) :604-612

[14] Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial [J].

Manns, Michael ;

Marcellin, Patrick ;

Poordad, Fred ;

Affonso de Araujo, Evaldo Stanislau ;

Buti, Maria ;

Horsmans, Yves ;

Janczewska, Ewa ;

Villamil, Federico ;

Scott, Jane ;

Peeters, Monika ;

Lenz, Oliver ;

Ouwerkerk-Mahadevan, Sivi ;

De La Rosa, Guy ;

Kalmeijer, Ronald ;

Sinha, Rekha ;

Beumont-Mauviel, Maria .

LANCET, 2014, 384 (9941) :414-426

[15] Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection [J].

McHutchison, John G. ;

Lawitz, Eric J. ;

Shiffman, Mitchell L. ;

Muir, Andrew J. ;

Galler, Greg W. ;

McCone, Jonathan ;

Nyberg, Lisa M. ;

Lee, William M. ;

Ghalib, Reem H. ;

Schiff, Eugene R. ;

Galati, Joseph S. ;

Bacon, Bruce R. ;

Davis, Mitchell N. ;

Mukhopadhyay, Pabak ;

Koury, Kenneth ;

Noviello, Stephanie ;

Pedicone, Lisa D. ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Sulkowski, Mark S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (06) :580-593

[16] Boceprevir for Untreated Chronic HCV Genotype 1 Infection [J].

Poordad, Fred ;

McCone, Jonathan, Jr. ;

Bacon, Bruce R. ;

Bruno, Savino ;

Manns, Michael P. ;

Sulkowski, Mark S. ;

Jacobson, Ira M. ;

Reddy, K. Rajender ;

Goodman, Zachary D. ;

Boparai, Navdeep ;

DiNubile, Mark J. ;

Sniukiene, Vilma ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Bronowicki, Jean-Pierre ;

Colombato, L. ;

Curciarello, J. ;

Silva, M. ;

Tanno, H. ;

Terg, R. ;

Adler, M. ;

Langlet, P. ;

Lasser, L. ;

Nevens, F. ;

Anderson, F. ;

Bailey, R. ;

Bilodeau, M. ;

Cooper, C. ;

Feinman, S. V. ;

Heathcote, J. ;

Levstik, M. ;

Ramji, A. ;

Sherman, M. ;

Shafran, S. ;

Yoshida, E. ;

Achim, A. ;

Ben Ali, S. ;

Bigard, M-A. ;

Bonny, C. ;

Bourliere, M. ;

Boyer-Darrigrand, N. ;

Bronowicki, J-P. ;

Canva, V. ;

Couzigou, P. ;

De Ledinghen, V. ;

Guyader, D. ;

Hezode, C. ;

Larrey, D. ;

Latournerie, M. ;

Marcellin, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1195-1206

[17]

Products Janssen, OL TM SIM FULL PRESC

[18]

Reddy KR, 2014, PHASE 3 RANDOMISED D

[19] Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection [J].

Sulkowski, Mark S. ;

Gardiner, David F. ;

Rodriguez-Torres, Maribel ;

Reddy, K. Rajender ;

Hassanein, Tarek ;

Jacobson, Ira ;

Lawitz, Eric ;

Lok, Anna S. ;

Hinestrosa, Federico ;

Thuluvath, Paul J. ;

Schwartz, Howard ;

Nelson, David R. ;

Everson, Gregory T. ;

Eley, Timothy ;

Wind-Rotolo, Megan ;

Huang, Shu-Pang ;

Gao, Min ;

Hernandez, Dennis ;

McPhee, Fiona ;

Sherman, Diane ;

Hindes, Robert ;

Symonds, William ;

Pasquinelli, Claudio ;

Grasela, Dennis M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (03) :211-221

[20]

WHO, 2003, WHO HDB REP RES CANC, P132

← 1 2 3 →